As payers intensify efforts to steer cases to lower-cost settings, ASCs are increasingly becoming a focal point in contracting. More payers are tying network participation and reimbursement to ...
Between 2017 and 2026, annual net inflation adjustments for ASCs have averaged 2.5%, according to a recent VMG Health report, which many ASC leaders say has failed to keep pace with rising costs.
In March 2025, Beam Therapeutics and its CEO John Evans announced the results of an early-stage but groundbreaking clinical trial: A single infusion of its gene-editing therapy fixed a genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results